Impact of simulated reduced injected dose on the assessment of amyloid PET scans.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: id:"swepub:oai:DiVA.org:uu-521120" > Impact of simulated...

1 av 1
Föregående post
Nästa post
Till träfflistan

Impact of simulated reduced injected dose on the assessment of amyloid PET scans.

Young, Peter (författare): Gothenburg University,Göteborgs universitet,University of Gothenburg,Wallenberg Centre for Molecular and Translational Medicine,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry,Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden

Heeman, Fiona, 1992 (författare): Gothenburg University,Göteborgs universitet,University of Gothenburg,Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands,Vrije Universiteit Amsterdam,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry

Axelsson, Jan, 1966- (författare): Umeå universitet,Umeå University,Radiofysik

visa fler...

Collij, Lyduine E. (författare): Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands; Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden,Amsterdam Neuroscience

Hitzel, Anne (författare): Department of Nuclear Medicine, Toulouse University Hospital, Toulouse, France

Sanaat, Amirhossein (författare): Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland

Niñerola-Baizan, Aida (författare): Nuclear Medicine Department, Hospital Clínic Barcelona, Barcelona, Spain; Biomedical Research Networking Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), ISCIII, Barcelona, Spain,CIBER Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)

Perissinotti, Andrés (författare): Nuclear Medicine Department, Hospital Clínic Barcelona, Barcelona, Spain; Biomedical Research Networking Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), ISCIII, Barcelona, Spain,CIBER Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)

Lubberink, Mark (författare): Uppsala University,Uppsala universitet,Radiologi,Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Frisoni, Giovanni B (författare): Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland; Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland,University of Geneva

Zaidi, Habib (författare): Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland; Geneva University Neurocenter, Geneva University, Geneva, Switzerland; Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands; Department of Nuclear Medicine, University of Southern Denmark, Odense, Denmark,University of Southern Denmark,University of Geneva,Geneva University Hospital

Barkhof, Frederik (författare): University College London,Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands; UCL Institute of Neurology, London, United Kingdom,Vrije Universiteit Amsterdam

Farrar, Gill (författare): GE Healthcare, Amersham, United Kingdom

Baker, Suzanne (författare): Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, United States; Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, United States,Lawrence Berkeley National Laboratory

Gispert, Juan Domingo (författare): Barcelona βeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain; Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain; Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain,Hospital del Mar Medical Research Institute,CIBER Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)

Garibotto, Valentina (författare): Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Geneva; NIMTLab; Center for Biomedical Imaging (CIBM), University of Geneva, Geneva, Switzerland

Rieckmann, Anna (författare): Bundeswehr University Munich,Institute for Psychology, Universität Der Bundeswehr München, Neubiberg, Germany

Schöll, Michael, 1980 (författare): Gothenburg University,Göteborgs universitet,University of Gothenburg,Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom; Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden,University College London,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry

visa färre...

(creator_code:org_t)

2024
2024
Engelska.
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - 1619-7070 .- 1619-7089. ; 51:3, s. 734-748

Relaterad länk:: http://dx.doi.org/10... (free); visa fler...; https://doi.org/10.1...; https://umu.diva-por... (primary) (Raw object); https://urn.kb.se/re...; https://doi.org/10.1...; https://lup.lub.lu.s...; https://gup.ub.gu.se...; https://urn.kb.se/re...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

PURPOSE: To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [18F]flutemetamol and [18F]florbetaben.METHODS: Cognitively impaired and unimpaired individuals (N = 250, 36% Aβ-positive) were included and injected with [18F]flutemetamol (N = 175) or [18F]florbetaben (N = 75). PET scans were acquired in list-mode (90-110 min post-injection) and reduced-dose images were simulated to generate images of 75, 50, 25, 12.5 and 5% of the original injected dose. Images were reconstructed using vendor-provided reconstruction tools and visually assessed for Aβ-pathology. SUVRs were calculated for a global cortical and three smaller regions using a cerebellar cortex reference tissue, and Centiloid was computed. Absolute and percentage differences in SUVR and CL were calculated between dose levels, and the ability to discriminate between Aβ- and Aβ + scans was evaluated using ROC analyses. Finally, intra-reader agreement between the reduced dose and 100% images was evaluated.RESULTS: At 5% injected dose, change in SUVR was 3.72% and 3.12%, with absolute change in Centiloid 3.35CL and 4.62CL, for [18F]flutemetamol and [18F]florbetaben, respectively. At 12.5% injected dose, percentage change in SUVR and absolute change in Centiloid were < 1.5%. AUCs for discriminating Aβ- from Aβ + scans were high (AUC ≥ 0.94) across dose levels, and visual assessment showed intra-reader agreement of > 80% for both tracers.CONCLUSION: This proof-of-concept study showed that for both [18F]flutemetamol and [18F]florbetaben, adequate quantitative and qualitative assessments can be obtained at 12.5% of the original injected dose. However, decisions to reduce the injected dose should be made considering the specific clinical or research circumstances.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)

Nyckelord

Alzheimer’s disease
Amyloid
Dose reduction
Neuroimaging
PET
Alzheimer’s disease
Amyloid
Dose reduction
Neuroimaging
PET
Alzheimer's disease

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

European Journal of Nuclear Medicine and Molecular Imaging (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Radiologi och bi ...

Artiklar i publikationen: European Journal ...

Av lärosätet: Uppsala universitet; Lunds universitet; Göteborgs universitet; Umeå universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se